Chris Delporte11.19.10
Yet more patient monitoring news from the MEDICA medical device trade fair in Dusseldorf, Germany. EarlySense, announced on Nov. 17 that it was winner of Popular Science magazine’s “Best of What’s New” award in the healthcare category. The feature will appear in the publication’s December issue.
EarlySense, which developed the EverOn patient supervision system for hospital and post acute care, is based in Ramat Can, Israel.
The EverOn System received clearance from the U.S. Food and Drug Administration (within the last five months) and has its CE Mark in Europe. It is approved for use in hospitals and homes and currently is installed at several medical centers in the United States and Europe.
The system activates immediately after a patient enters the bed. It activates using a contact-free sensor that slips under the mattress and never touches the patient.The system records and documents cardiac, respiratory and motion parameters for up to 36 patients at a time and alerts staff when thresholds are crossed, as well as if a patient needs turning to avoid pressure ulcers or is leaving the bed and is in danger of falling. Nurses are informed of patient status changes on the patient’s bedside monitor, at the nurse’s station, on their mobile phones and on a large screen display mounted in a prominent spot on the wall in the department.
“The EverOn, through the early identification of warning signs, empowers clinicians to provide proactive, personalized care,” said Avner Halperin, CEO of EarlySense.
According to Halperin, hospitals using the system achieve better clinical and economic outcomes.He predicted that EverOn would be become a standard of care in hospitals. “We are delighted that Popular Science recognizes this,” he added, noting that early detection of deterioration is proven to encourage proactive intervention, which reduces “never events” and secures better patient outcomes. (Editor's note: "Never events" are adverse events that are serious, largely preventable, and of concern to both the public and healthcare providers for the purpose of public accountability.)
Founded in 1872, Popular Science has a circulation of 1.3 million and 7.1 million monthly readers. The magazine reports on the intersection of science and everyday life.
In late October, EarlySense closed an additional $7 million Series D round of financing round led by JK&B Capital in Chicago, Ill. Pitango Venture Capital (with offices in Israel and California) and other existing investors also participated. This round augments the C Round closed, which closed in 2010. The total amount raised in 2010 was $20 million.
According to the company, as a result of “favorable market responses,” the financing will be used to accelerate the global market launch of the EverOn system. To date, EarlySense has raised $31 million.
“EverOn has already proven to make a significant difference in hospitals in the U.S. We know for a fact that it has saved lives, shortened hospital stays, and has saved money for hospitals. EarlySense is clearly a market leader and its EverOn system is quickly becoming an industry standard. We are enthusiastic about this very promising company and its existing and future impact on healthcare worldwide,” said David Kronfeld, founder of JK&B.
Pitango first invested in EarlySense in June when it led the C round.
Ittai Harel, a partner at Pitango and a member of EarlySense’s board of directors, said his firm had high hopes for the company.
“Just a few short months later, our commitment is even stronger, as each day brings additional accounts of how the EverOn system helped to make apositive difference for both patients and healthcare providers,” Harel said.
Halperin said the future looks “promising” based on meeting several milestones during the past year.
“This year has been outstanding from all standpoints: financial, regulatory, clinical and marketwise,” he said. “Just recently, the latest EverOn clinical study findings were published by the Journal of Medical Engineering and Technology. The results found the system to be accurate in accordance with regulatory and industry criteria.”
EarlySense, which developed the EverOn patient supervision system for hospital and post acute care, is based in Ramat Can, Israel.
The EverOn System received clearance from the U.S. Food and Drug Administration (within the last five months) and has its CE Mark in Europe. It is approved for use in hospitals and homes and currently is installed at several medical centers in the United States and Europe.
The system activates immediately after a patient enters the bed. It activates using a contact-free sensor that slips under the mattress and never touches the patient.The system records and documents cardiac, respiratory and motion parameters for up to 36 patients at a time and alerts staff when thresholds are crossed, as well as if a patient needs turning to avoid pressure ulcers or is leaving the bed and is in danger of falling. Nurses are informed of patient status changes on the patient’s bedside monitor, at the nurse’s station, on their mobile phones and on a large screen display mounted in a prominent spot on the wall in the department.
“The EverOn, through the early identification of warning signs, empowers clinicians to provide proactive, personalized care,” said Avner Halperin, CEO of EarlySense.
According to Halperin, hospitals using the system achieve better clinical and economic outcomes.He predicted that EverOn would be become a standard of care in hospitals. “We are delighted that Popular Science recognizes this,” he added, noting that early detection of deterioration is proven to encourage proactive intervention, which reduces “never events” and secures better patient outcomes. (Editor's note: "Never events" are adverse events that are serious, largely preventable, and of concern to both the public and healthcare providers for the purpose of public accountability.)
Founded in 1872, Popular Science has a circulation of 1.3 million and 7.1 million monthly readers. The magazine reports on the intersection of science and everyday life.
In late October, EarlySense closed an additional $7 million Series D round of financing round led by JK&B Capital in Chicago, Ill. Pitango Venture Capital (with offices in Israel and California) and other existing investors also participated. This round augments the C Round closed, which closed in 2010. The total amount raised in 2010 was $20 million.
According to the company, as a result of “favorable market responses,” the financing will be used to accelerate the global market launch of the EverOn system. To date, EarlySense has raised $31 million.
“EverOn has already proven to make a significant difference in hospitals in the U.S. We know for a fact that it has saved lives, shortened hospital stays, and has saved money for hospitals. EarlySense is clearly a market leader and its EverOn system is quickly becoming an industry standard. We are enthusiastic about this very promising company and its existing and future impact on healthcare worldwide,” said David Kronfeld, founder of JK&B.
Pitango first invested in EarlySense in June when it led the C round.
Ittai Harel, a partner at Pitango and a member of EarlySense’s board of directors, said his firm had high hopes for the company.
“Just a few short months later, our commitment is even stronger, as each day brings additional accounts of how the EverOn system helped to make apositive difference for both patients and healthcare providers,” Harel said.
Halperin said the future looks “promising” based on meeting several milestones during the past year.
“This year has been outstanding from all standpoints: financial, regulatory, clinical and marketwise,” he said. “Just recently, the latest EverOn clinical study findings were published by the Journal of Medical Engineering and Technology. The results found the system to be accurate in accordance with regulatory and industry criteria.”